Summary & Overview
HCPCS M0250: Tocilizumab Intravenous Infusion for Hospitalized COVID-19 Patients
HCPCS Level II code M0250 covers intravenous tocilizumab infusion, including administration, post-infusion monitoring, and a second dose for hospitalized patients (ages 2+) with COVID-19 who are on systemic corticosteroids and require supplemental oxygen, mechanical ventilation, or ECMO. The code is nationally significant given tocilizumab's role in treating severe COVID-19 and its use in hospital and critical-care settings where timely biologic therapy can affect clinical trajectories.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of payment and coverage benchmarks, typical billing and service-line context for inpatient therapeutics, and relevant clinical inclusion criteria reflected in the code description. The publication summarizes common modifier usage and administrative considerations where available, and highlights where input data was not provided.
This summary is intended for hospital billing managers, revenue-cycle professionals, and policy analysts seeking a concise reference to how M0250 is defined and applied across major national payers, with context on service setting and clinical indications.
Billing Code Overview
HCPCS Level II code M0250 describes an intravenous infusion of tocilizumab for hospitalized adult and pediatric patients (2 years and older) with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). The descriptor includes administration of the infusion, post-administration monitoring, and a second dose when applicable.
-
Service type: Therapeutic intravenous infusion of a monoclonal antibody (tocilizumab) for inpatient COVID-19 care
-
Typical site of service: Hospital inpatient setting, including critical care areas where patients receive supplemental oxygen, non-invasive or invasive ventilation, or ECMO
Clinical & Coding Specifications
Clinical Context
A hospitalized adult or pediatric patient (≥2 years) with confirmed COVID-19 develops progressive hypoxemic respiratory failure despite systemic corticosteroid therapy. The patient requires supplemental oxygen via nasal cannula, high-flow oxygen, non-invasive positive pressure ventilation, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). After multidisciplinary review and meeting institutional criteria for immunomodulatory therapy, the patient is scheduled for an intravenous infusion of tocilizumab. The clinical workflow includes: admission to an inpatient unit or ICU; confirmation of eligibility (age ≥2 years, ongoing corticosteroid therapy, oxygen/ventilatory support requirement); obtaining informed consent; baseline labs (CBC, liver function tests, inflammatory markers); pharmacy verification and preparation of tocilizumab dose; infusion via IV line with continuous monitoring during administration and for a defined post-administration observation period for infusion reactions or clinical deterioration; documentation of dose, lot number, and time; and provision for a second dose per protocol when clinically indicated. Typical site of service is an inpatient acute care hospital or intensive care unit. Typical modifiers applied reflect billing circumstances such as professional/technical components, unusual procedural difficulty, or bilateral/multiple procedures as appropriate to the encounter.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — standard report of the service |